OrphoMed: OrphoMed to Present Phase 1 Results of ORP101 at Digestive Disease Week 2020
ORP101 Currently in Phase 2 Study for Treatment of Irritable Bowel Syndrome with Diarrhea OrphoMed Inc. a clinicalstage biopharmaceutical company today announced the presentation at Digestive Disease Week DDW of Phase 1 data for its lead candidate ORP101 ...
Read full article »
OrphoMed is a biopharmaceutical company that develops dimer therapies for visceral hypersensitivity and hypermotility in gastrointestinal disorders.
Read more